Voyager Therapeutics (NASDAQ:VYGR) has been given a $35.00 target price by investment analysts at Canaccord Genuity in a research report issued on Wednesday, March 14th. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective points to a potential upside of 101.50% from the company’s current price.
Other research analysts also recently issued reports about the company. BidaskClub downgraded Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. BTIG Research initiated coverage on Voyager Therapeutics in a research note on Tuesday, December 19th. They issued a “buy” rating and a $32.00 price objective for the company. Piper Jaffray reissued a “buy” rating and issued a $40.00 price objective on shares of Voyager Therapeutics in a research note on Monday, March 12th. Zacks Investment Research raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 6th. Finally, Wedbush cut Voyager Therapeutics from an “outperform” rating to a “neutral” rating and set a $29.00 price target for the company. in a report on Monday, March 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. Voyager Therapeutics currently has an average rating of “Buy” and a consensus price target of $29.73.
NASDAQ VYGR traded down $0.76 during trading hours on Wednesday, reaching $17.37. The stock had a trading volume of 214,523 shares, compared to its average volume of 439,337. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $31.91. The firm has a market cap of $619.66, a P/E ratio of -6.58 and a beta of 2.97.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.40) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.32. The business had revenue of $6.35 million for the quarter, compared to analyst estimates of $5.81 million. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. sell-side analysts anticipate that Voyager Therapeutics will post -2.54 earnings per share for the current year.
In other news, insider Bernard Ravina sold 3,630 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total transaction of $59,532.00. Following the sale, the insider now owns 7,353 shares of the company’s stock, valued at approximately $120,589.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jane Henderson sold 11,200 shares of the firm’s stock in a transaction dated Friday, March 23rd. The stock was sold at an average price of $20.52, for a total value of $229,824.00. Following the sale, the chief financial officer now directly owns 19,900 shares in the company, valued at approximately $408,348. The disclosure for this sale can be found here. Insiders have sold a total of 68,087 shares of company stock worth $1,588,741 in the last three months. Corporate insiders own 8.00% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Voyager Therapeutics by 73.9% during the fourth quarter. BlackRock Inc. now owns 1,210,763 shares of the company’s stock worth $20,099,000 after buying an additional 514,345 shares during the period. Farallon Capital Management LLC increased its position in Voyager Therapeutics by 290.5% during the fourth quarter. Farallon Capital Management LLC now owns 654,812 shares of the company’s stock worth $10,870,000 after buying an additional 487,147 shares during the period. Wells Fargo & Company MN increased its position in Voyager Therapeutics by 19.2% during the fourth quarter. Wells Fargo & Company MN now owns 449,525 shares of the company’s stock worth $7,462,000 after buying an additional 72,335 shares during the period. Vanguard Group Inc. increased its position in Voyager Therapeutics by 3.2% during the second quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after buying an additional 13,194 shares during the period. Finally, AXA purchased a new position in shares of Voyager Therapeutics in the 4th quarter valued at approximately $5,591,000. 78.22% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Voyager Therapeutics (NASDAQ:VYGR) Given a $35.00 Price Target by Canaccord Genuity Analysts” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/voyager-therapeutics-vygr-pt-set-at-35-00-by-canaccord-genuity.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.